References
- Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006;27:465-90
- Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8
- Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92
- Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens 2011;1:244-51
- Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50
- Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
- Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 Express). Hypertension 2003;42:1206-52
- Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
- Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
- Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid- lowering therapy. Arch Intern Med 2005;165:1147-52
- Rottlaender D, Scherner M, Schneider T, et al. Multimedikation, Compliance und Zusatzmedikation bei Patienten mit kardiovaskulären Erkrankungen [Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany]. [Article in German] Dtsch Med Wochenschr 2007;132:139-44
- Bangalore S, Shahane A, Parkar S, et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007;9:184-9
- da Silva PM. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. Clin Drug Investig 2010;30:625-41
- Flack JM, Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension. Expert Opin Pharmacother 2009;10:1979-94
- Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
- Lacourcière Y, Crikelair N, Glazer RD, et al. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens 2011;25:615-22
- Hagendorff A, Freytag S, Müller A, et al. Pill burden in hypertensive patients treated with single-pill combination therapy – An Observational Study. Adv Ther 2013;30:406-19
- Theobald K, Capan M, Herbold M, et al. Quality assurance in non-interventional studies. GMS Ger Med Sci 2009;7:Doc 29
- Calhoun DA, Lacourcière Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54:32-9
- Duprez D, Ferdinand K, Purkayastha D, et al. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Vasc Health Risk Manag 2011;7:701-8
- Fogari R, Zoppi A, Mugellini A, et al. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert Opin Pharmacother 2012;13:629-36
- Fogari R, Zoppi A, Mugellini A, et al. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opin Pharmacother 2012;13:1091-9
- Lu CY. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract 2009;63:691-7
- Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-8
- von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9